Home › Funds › PSP Research LLC › RARE

PSP Research LLC position in RARE

ULTRAGENYX PHARMACEUTICAL IN · Health Care

PSP Research LLC reported holding 17,000 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$568K, representing 0.30% of its reported portfolio and ranking #9 among its reported holdings. PSP Research LLC has disclosed RARE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)17.00K sh
Reported value held$567.63K
Portfolio Weight0.30%
First reportedQ1 2026
Last changeNew

How PSP Research LLC's RARE position evolved

PSP Research LLC first disclosed a stake in RARE in Q1 2026 at 22,100 shares (US$463K). The position peaked in Q2 2026 at 17,000 shares, worth US$568K. Across 2 filings, PSP Research LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 17,000 shares valued at US$568K.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 22.10K $463.00K New
Q2 2026 17.00K $567.63K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RARE and 13F data

RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RARE

All RARE fund holders →